The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination
Randomized, Double-Blind, Study to Assess Low-Dose Naltrexone and Acetaminophen Combination in the Prevention of Episodic Migraine in Adults
Sponsor: Allodynic Therapeutics, Inc
Listed as NCT03194555, this PHASE2 trial focuses on Migraine With or Without Aura and remains completed. Sponsored by Allodynic Therapeutics, Inc, it has been updated 15 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
May 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2024 — May 2024 [monthly]
Completed PHASE2
-
May 2021 — Jan 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed · Phase: PHASE2_PHASE3 → PHASE2
▶ Show 10 earlier versions
-
Jan 2021 — May 2021 [monthly]
Unknown Status PHASE2_PHASE3
-
May 2020 — Jan 2021 [monthly]
Unknown Status PHASE2_PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — May 2020 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2017 — Apr 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Nov 2017 — Dec 2017 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2017 — Nov 2017 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Aug 2017 — Sep 2017 [monthly]
Not Yet Recruiting PHASE2_PHASE3
-
Jul 2017 — Aug 2017 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Allodynic Therapeutics, Inc
For direct contact, visit the study record on ClinicalTrials.gov .